New hope drug enters human testing for tough cancers
NCT ID NCT07391644
Summary
This is the first study in people to test a new cancer drug called JSKN027. Researchers will give the drug to patients with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug causes tumors to shrink, starting with a small group and then expanding to more patients with specific cancers like lung, colon, and liver cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.